At the core of MD Anderson’s approach to exceptional patient care is a virtuous cycle of innovation that's grounded in collaboration, connectivity and data-based science. Our unique environment and vast resources accelerate novel concepts faster than ever before by offering leading scientific minds close proximity to our clinics to ease collaboration with our renowned clinicians and our patient partners.
At the 2023 American Association for Cancer Research Annual Meeting, our experts will showcase their pacesetting research and join colleagues from across the globe for discussion on the latest advances in cancer science.
Below are highlights from our presentations, details about onsite networking opportunities with our experts and information on open research positions at MD Anderson.
Comprehensive analysis highlights differences between brain metastases and other tumor sites, identifying potential therapeutic targets
MD Anderson researchers present targeted therapy results from two clinical trial findings
Study provides framework for personalizing treatment approaches and developing combination strategies for KRAS G12C-mutant lung cancer
Meet the Experts
Visit booth 1501 to discuss hot topics and emerging trends with leading minds in cancer science.
Sunday, April 16
Monday, April 17
Tuesday, April 18
Our research by the numbers
invested in research
From Sept. 1, 2021-Aug. 31, 2022.
Education and Training at MD Anderson
MD Anderson academic programs are competitive and comprehensive. We offer educational opportunities from undergraduate degrees to postdoctoral training.
James P. Allison Institute
The James P. Allison Institute is dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health. The institute builds upon the legacy of its namesake, James P. Allison, Ph.D., who was awarded the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer.
Meet Dr. James Allison at the 2023 AACR Annual Meeting on Tuesday, April 18 from 3-4 p.m.
Our Therapeutics Discovery team consists of dedicated cancer researchers, doctors, drug developers and scientific experts. We develop small molecule drugs, biologics and cellular therapies without the bottlenecks that hamper traditional drug development.
We're inspired by the needs of our patients and guided by the expertise of MD Anderson clinicians. We don't bring the “bench to bedside” – we start with the bench at the bedside – with each patient and their cancer.